Abstract:63 Background: Chemoradiotherapy followed by radical surgery is standard treatment for patients with locally advanced rectal cancer (LARC). Short-course radiotherapy (SCRT), either with immediate or delayed surgery, provides similar oncological results compared with long-course radiotherapy with delayed surgery. Delayed surgery with the addition of neoadjuvant immunotherapy may bring better downstaging effect and minimize the risk of distant relapse. We conducted this single-arm phase 2 trial to investigate the efficacy and safety of SCRT combined with subsequent capecitabine and oxaliplatin (CAPOX) plus Camrelizumab (anti-PD-1 antibody) followed by delayed surgery in patients with LARC. Methods: Patients with histologically confirmed T3–4N0M0 or T1-4N+M0 rectal cancer, previously untreated disease, and ECOG performance status of 0-1, received SCRT (5×5 Gy) with subsequent two 21-day cycles of CAPOX (oxaliplatin 130 mg/m2 ivgtt, d1; capecitabine 1000 mg/m2 po bid, d1-14) plus Camrelizumab (200 mg iv drip, d1) after 1 week, followed by radical surgery after 1 week. Adjuvant therapy was decided by the investigator. The primary endpoint was pathological complete response (pCR) rate, defined as the absence of viable tumor cells in the primary tumor and lymph nodes. The study is ongoing to follow up the survival outcomes and obtain the results of next generation sequencing and PD-L1 expression. The data cutoff date was September 8, 2020. Results: From November 2019 to September 2020, a targeted number of patients (n = 29) were enrolled and are expected to complete the surgery by November 2020. The median age was 57 (range 31-73) years, 55% (16/29) of patients had ECOG performance status of 1, and the median distance from tumor to the anal verge was 5 (range, 1.9-9) cm. At data cutoff, 10 patients had undergone the surgery, with R0 resection rate of 100%. The pCR rate was 60% (6/10), including 56% (5/9) for those with mismatch repair-proficient, and 100% (1/1) for those with mismatch repair-deficient. Of 4 patients without pCR, 2 only received one cycle of CAPOX plus Camrelizumab due to the outbreak of COVID-19 in Wuhan, and 1 had signet-ring cell rectal carcinoma. At data cutoff, 20 patients had received at least one dose of Camrelizumab. Immune-related adverse events (irAEs) were all grade 1-2, and the most common irAE was reactive cutaneous capillary endothelial proliferation in 10 (50%) of 20 patients. Postoperative bleeding and infection occurred in 1 (10%) and 2 (20%) of 10 patients, respectively. No treatment-related death was observed. Conclusions: SCRT combined with subsequent CAPOX plus Camrelizumab followed by delayed surgery showed promising pCR rate with good tolerance in patients with LARC, regardless of the mismatch repair status, suggesting a candidate strategy for the neoadjuvant therapy. Clinical trial information: NCT04231552.

Randomized Phase II Trial of Preoperative Chemoradiotherapy with or Without Cetuximab in Locally Advanced Rectal Adenocarcinoma.

Phase II Study of Neoadjuvant Short-Course Radiotherapy Combined with CAPEOX Plus Envafolimab in Patients with Microsatellite Stable Locally Advanced Rectal Cancer: Updated Results of PRECAM Study.

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002)

Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer

The efficacy and safety of short-course radiotherapy followed by sequential chemotherapy and Cadonilimab for locally advanced rectal cancer: a protocol of a phase II study

Phase II Study of Pembrolizumab after Chemoradiotherapy (CRT) As Adjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma (LA-ESCC) Patients at High Risk of Recurrence Following Preoperative CRT Plus Surgery.

LBA25 Neoadjuvant Short-Course Radiotherapy Followed by Camrelizumab Plus Chemotherapy Versus Long-Course Chemoradiotherapy Followed by Chemotherapy in Locally Advanced Rectal Cancer: A Randomized Phase III Trial (UNION)

Efficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: A phase II PRECAM experimental study

Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before surgery in patients with locally advanced rectal cancer (A phase II study)

Preoperative Cetuximab and Radiation (XRT) for Patients (pts) with Surgically Resectable Esophageal and Gastroesophageal Junction (GEJ) Carcinomas: A Pilot Study from the Hoosier Oncology Group and the University of Texas Southwestern

Short-course Radiotherapy and Subsequent CAPOX Plus Camrelizumab Followed by Delayed Surgery for Locally Advanced Rectal Cancer:Short-Term Results of a Phase II Trial.

Short-course Radiotherapy (SCRT) Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Total Neoadjuvant Therapy of Locally Advanced Rectal Cancer (LARC): A Multicenter, Single-Arm, Open-Label, Phase II Study.

Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients with KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases.

Neoadjuvant Short-Course Radiotherapy Followed by Chemotherapy Plus Camrelizumab Versus Long-Course Chemoradiotherapy Followed by Chemotherapy for Patients with Locally Advanced Rectal Cancer: A Randomized, Multicenter, Open-Label Phase 3 Trial (Union).

Neoadjuvant Long-Course Chemoradiation Plus PD1 Blockade for Locally Advanced Rectal Cancer: Results of a Phase 2, Open-Label, Randomized Controlled Trial.

Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma

Three-year Survival Data from a Phase 2 Trial of Neoadjuvant Short-Course Radiotherapy Followed by Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer.

Neoadjuvant Sandwich Treatment with Oxaliplatin and Capecitabine Administered Prior To, Concurrently With, and Following Radiation Therapy in Locally Advanced Rectal Cancer: a Prospective Phase 2 Trial.

Preoperative short-course radiotherapy followed by consolidation chemotherapy for treatment with locally advanced rectal cancer: a meta-analysis

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial